4.6 Article

Prognostic significance of nucleolar assessment in invasive breast cancer

期刊

HISTOPATHOLOGY
卷 76, 期 5, 页码 671-684

出版社

WILEY
DOI: 10.1111/his.14036

关键词

invasive breast cancer; methods; nucleoli; prognosis

资金

  1. Egyptian Ministry of Higher Education and Scientific Research
  2. Innovate UK (PathLAKE consortium)

向作者/读者索取更多资源

Aims Nucleolar morphometric features have a potential role in the assessment of the aggressiveness of many cancers. However, the role of nucleoli in invasive breast cancer (BC) is still unclear. The aims of this study were to investigate the optimal method for scoring nucleoli in IBC and their prognostic significance, and to refine the grading of breast cancer (BC) by incorporating nucleolar score. Methods and results Digital images acquired from haematoxylin and eosin-stained sections from a large BC cohort were divided into training (n = 400) and validation (n = 1200) sets for use in this study. Four different assessment methods were evaluated in the training set to identify the optimal method associated with the best performance and significant prognostic value. These were: (i) a modified Helpap method; (ii) counting prominent nucleoli (size >= 2.5 mu m) in 10 field views (FVs); (iii) counting prominent nucleoli in five FVs; and (iv) counting prominent nucleoli in one FV. The optimal method was applied to the validation set and to an external validation set, i.e. data from The Cancer Genome Atlas (n = 743). Scoring prominent nucleoli in five FVs showed the highest interobserver concordance rate (intraclass correlation coefficient of 0.8) and a significant association with BC-specific survival (P < 0.0001). A high nucleolar score was associated with younger age, larger tumour size, and higher grade. Incorporation of nucleolar score in the Nottingham grading system resulted in a higher significant association with survival than the conventional grade. Conclusions Quantification of nucleolar prominence in five FVs is a cost-efficient and reproducible morphological feature that can predict BC behaviour and can provide an alternative to pleomorphism to improve BC grading performance.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Reproductive Biology

Chitosan coating does not prevent the effect of the transfer of green silver nanoparticles biosynthesized by Streptomyces malachitus into fetuses via the placenta

Khloud Elsharawy, Mohamed Abou-Dobara, Hekmat El-Gammal, Ayman Hyder

REPRODUCTIVE BIOLOGY (2020)

Review Cell Biology

Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype

Yousif A. Kariri, Mohammed A. Aleskandarany, Chitra Joseph, Sasagu Kurozumi, Omar J. Mohammed, Michael S. Toss, Andrew R. Green, Emad A. Rakha

PATHOBIOLOGY (2020)

Article Oncology

The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer

Khloud A. Elsharawy, Omar J. Mohammed, Mohammed A. Aleskandarany, Ayman Hyder, Hekmat L. El-Gammal, Mohamed I. Abou-Dobara, Andrew R. Green, Leslie W. Dalton, Emad A. Rakha

BRITISH JOURNAL OF CANCER (2020)

Article Pathology

Ran GTPase is an independent prognostic marker in malignant melanoma which promotes tumour cell migration and invasion

Somaia Elsheikh, Ilias Kouzoukakis, Catherine Fielden, Wei Li, Shaimaa Elsaid Lashin, Nadia Khair, Teresa Pereira Raposo, Wakkas Fadhil, Philip Rudland, Mohammed Aleskandarany, Poulam Patel, Mohamed El--Tanani, Mohammad Ilyas

Summary: Ran is an overexpressed poor prognostic marker in malignant melanoma. It promotes cell motility through upregulation of the oncogene c-Met, potentially leading to metastasis.

JOURNAL OF CLINICAL PATHOLOGY (2022)

Article Cell Biology

Artificial intelligence grading of breast cancer: a promising method to refine prognostic classification for management precision

Khloud A. Elsharawy, Thomas A. Gerds, Emad A. Rakha, Leslie W. Dalton

Summary: The study evaluated the potential value of AI-based breast cancer grading at the molecular level and in predicting patient outcomes. Results showed that AI grade has promise in predicting patient outcomes, gene discovery, and providing second opinions.

HISTOPATHOLOGY (2021)

Article Oncology

Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer

Maryam Althobiti, Khloud A. El-sharawy, Chitra Joseph, Mohammed Aleskandarany, Michael S. Toss, Andrew R. Green, Emad A. Rakha

Summary: SLC39A6 may have prognostic value for a better outcome in ER + luminal breast cancer, with high expression being associated with longer BC-specific survival even in patients who did not receive endocrine therapy. Further functional studies on the role of SLC39A6 in ER + luminal breast cancer are warranted.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Article Oncology

Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer

Yousif Kariri, Michael S. Toss, Mansour Alsaleem, Khloud A. Elsharawy, Chitra Joseph, Nigel P. Mongan, Andrew R. Green, Emad A. Rakha

Summary: The study reveals that UBE2C is an independent prognostic biomarker in invasive breast cancer, with high expression of UBE2C associated with poor prognosis and correlated with other prognostic indicators and tumor characteristics. These findings suggest that UBE2C could be a potential therapeutic target in breast cancer.

BREAST CANCER RESEARCH AND TREATMENT (2022)

Article Oncology

Hypoxia Drives Centrosome Amplification in Cancer Cells via HIF1α-Dependent Induction of Polo-Like Kinase 4

Karuna Mittal, Jaspreet Kaur, Shaligram Sharma, Nivya Sharma, Guanhao Wei, Ishita Choudhary, Precious Imhansi-Jacob, Nagini Maganti, Shrikant Pawar, Padmashree Rida, Michael S. Toss, Mohammed Aleskandarany, Emiel A. Janssen, Havard Soiland, Meenakshi Gupta, Michelle D. Reid, Emad A. Rakha, Ritu Aneja

Summary: Hypoxia promotes centrosome amplification (CA) by upregulating PLK4 via HIF1 alpha. High levels of HIF1A and PLK4 are associated with poor overall survival in breast cancer and PDAC patients, indicating the significance of HIF1 alpha and PLK4 in prognosis. The findings suggest that HIF1 alpha-induced CA through direct upregulation of PLK4 could serve as a potential risk stratification marker and therapeutic target for CA-rich cancers.

MOLECULAR CANCER RESEARCH (2022)

Article Biochemistry & Molecular Biology

A Case Series Exploration of Multi-Regional Expression Heterogeneity in Triple-Negative Breast Cancer Patients

Qi Xu, Jaspreet Kaur, Dennis Wylie, Karuna Mittal, Hongxiao Li, Rishab Kolachina, Mohammed Aleskandarany, Michael S. Toss, Andrew R. Green, Jianchen Yang, Thomas E. Yankeelov, Shristi Bhattarai, Emiel A. M. Janssen, Jun Kong, Emad A. Rakha, Jeanne Kowalski, Ritu Aneja

Summary: This study explores the intratumoral heterogeneity (ITH) in triple-negative breast cancer (TNBC) by evaluating gene expression and imaging differences within the same tumor. The results show extensive intertumoral heterogeneity and regional ITH in gene expression and image-derived features in TNBC. Concerns are raised regarding gene expression based TNBC subtyping.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Oncology

Mechanistic and Clinical Evidence Supports a Key Role for Cell Division Cycle Associated 5 (CDCA5) as an Independent Predictor of Outcome in Invasive Breast Cancer

Yousif A. Kariri, Chitra Joseph, Mansour A. Alsaleem, Khloud A. Elsharawy, Sami Alsaeed, Michael S. Toss, Nigel P. Mongan, Andrew R. Green, Emad A. Rakha

Summary: Breast cancer exhibits genetic and clinical heterogeneity. This study evaluates the prognostic and biological value of Cell Division Cycle Associated 5 (CDCA5) in breast cancer. The results demonstrate that CDCA5 plays an important role in breast cancer development and metastasis, and could be used as a potential biomarker for disease progression.

CANCERS (2022)

Article Oncology

Upregulation of Cyclin B2 (CCNB2) in breast cancer contributes to the development of lymphovascular invasion

Abrar Aljohani, Michael S. Toss, Khloud A. El-Sharawy, Sameer Mirza, Graham R. Ball, Andrew R. Green, Emad A. Rakha

Summary: Lymphovascular invasion (LVI) is a crucial step in breast cancer (BC) metastasis, and CCNB2 plays an important regulatory role in LVI. Knockdown of CCNB2 inhibits BC cell migration and proliferation, blocks the cell cycle, and reduces apoptotic cell count. High CCNB2 protein expression is associated with other aggressive behavior features and shorter survival. Therefore, CCNB2 may be a promising therapeutic target to inhibit LVI and reduce metastatic events.

AMERICAN JOURNAL OF CANCER RESEARCH (2022)

Article Oncology

Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer

Khloud A. Elsharawy, Maryam Althobiti, Omar J. Mohammed, Abrar I. Aljohani, Michael S. Toss, Andrew R. Green, Emad A. Rakha

Summary: NOP10 is a key factor in ribosome biogenesis and telomere maintenance, and its high expression is significantly associated with aggressive features in breast cancer, especially in the triple-negative breast cancer subtype. High NOP10 protein expression is an independent predictor of poor outcome, shorter survival, and higher risks of death and distant metastasis in chemotherapy-treated patients. This suggests that NOP10 may serve as a potential prognostic biomarker and predictive indicator for chemotherapy resistance in breast cancer.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Meeting Abstract Oncology

HSP90AA1 significance as a target in breast cancer

Sami A. Alsaeed, Mohammed A. Aleskandarany, Sasagu Kurozumi, Chitra Joseph, Mansour Alsaleem, Michael Toss, Nigel P. Mongan, Ian O. Ellis, Andrew R. Green, Emad A. Rakha

BREAST CANCER RESEARCH AND TREATMENT (2020)

Meeting Abstract Oncology

Comprehensive transcriptomic profiling reveals perplakin as a novel independent predictor of outcome in triple-negative breast cancer

Mansour Alsaleem, Chitra Joseph, Pavan Narsimha, Michael Toss, Graham Ball, Sara Raafat, Mohammed Aleskandarany, Angela Ogdon, Padmashree Rida, Andrew Green, Ian Ellis, Ritu Aneja, Nigel Mongan, Emad Rakha

BREAST CANCER RESEARCH AND TREATMENT (2020)

暂无数据